RTP Mobile Logo
Oncology Practice Update, Issue 1, 2010
Released April 2010

Featuring interviews with Drs Robert Z Orlowski and Hyman B Muss. (Audio Content)

CE Disclosures and Faculty Information


    The past decade has marked an explosion in the number of new agents and regimens available for the treatment of the most common solid tumors and hematologic cancer afflicting the population at large. One of the most confounding aspects of cancer management is that almost every one of the drugs utilized to provide a potential cure, prolong life or palliate disease-related symptoms brings with it bothersome, debilitating or potentially fatal side effects that can dramatically limit the duration of therapy, attenuate long-term survival and affect quality of life in both the short and long term.

    Historically, the clinician’s focus on side-effect management related mainly to those toxicities associated with chemotherapeutic agents. Although that continues to be a challenge, the recent introduction of new targeted therapies has forced these individuals to suddenly wear a number of primary care hats in order to manage a spectrum of novel toxicities. As such, now more than ever clinicians need educational activities focused on this crucial aspect of cancer management.

    This unique activity will provide practicing oncology clinicians access to the opinions of oncology clinical investigators with expertise in the management of toxicities related to cancer and its treatment. This will help them increase their knowledge base, stay up to date and optimally deliver state-of-the-art, comprehensive, therapeutic and supportive care for patients with cancer.


    • Discuss the benefits and risks associated with therapies used in the treatment of breast cancer and multiple myeloma, including bone-targeted agents, immunomodulatory drugs, proteasome inhibitors, chemotherapy regimens and aromatase inhibitors.
    • Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
    • Recommend evidence-based alternative therapies when treatment-induced toxicities adversely affect quality of life.


    Nurse Practitioners and Nurses: This educational activity for 1.5 contact hours is provided by Research To Practice during the period of April 2010 to April 2011.

    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    CME credit is no longer available for this issue


    Physicians and Physician Assistants: Research To Practice designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians and Physician Assistants should only claim credit commensurate with the extent of their participation in the activity.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    This is an audio CNE/CME program. The participant should review the CNE/CME information and listen to the audio MP3s. This website also includes links to relevant abstracts and full-text articles.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE/CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr OrlowskiSponsored Research Agreement: Celgene Corporation, Centocor Ortho Biotech Services LLC, Millennium Pharmaceuticals Inc. Dr MussConsulting Agreements: Abraxis BioScience, Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Pfizer Inc, Roche Laboratories Inc, Sandoz, Wyeth.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CNE/CME activities from the following commercial interests: Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Services LLC, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

    This program is supported by educational grants from Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Millennium Pharmaceuticals Inc and Sanofi-Aventis.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date:
    April 2010
    Expiration date: April 2011

Acknowledge and close

Oncology Practice Update, Issue 1, 2010
Released April 2010

Featuring interviews with Drs Robert Z Orlowski and Hyman B Muss. (Audio Content)